Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson’s disease
Open accessThe DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.
Abstract
Heterozygous mutations in GBA1, the gene encoding lysosomal glucocerebrosidase, are the most frequent known genetic risk factor for Parkinson's disease. Reduced glucocerebrosidase and α-synuclein accumulation are directly related in cell models of Parkinson's disease. We investigated relationships between Parkinson's disease-specific glucocerebrosidase deficits, glucocerebrosidase-related pathways, and α-synuclein levels in brain tissue from subjects with sporadic Parkinson's disease without GBA1 mutations. Brain regions with and without a Parkinson's disease-related increase in α-synuclein levels were assessed in autopsy samples from subjects with sporadic Parkinson's disease (n = 19) and age- and post-mortem delay-matched controls (n = 10). Levels of glucocerebrosidase, α-synuclein and related lysosomal and autophagic proteins were assessed by western blotting. Glucocerebrosidase enzyme activity was measured using a fluorimetric assay, and glucocerebrosidase and α-synuclein messenger RNA expression determined by quantitative polymerase chain reaction. Related sphingolipids were analysed by mass spectrometry. Multivariate statistical analyses were performed to identify differences between disease groups and regions, with non-parametric correlations used to identify relationships between variables. Glucocerebrosidase protein levels and enzyme activity were selectively reduced in the early stages of Parkinson's disease in regions with increased α-synuclein levels although limited inclusion formation, whereas GBA1 messenger RNA expression was non-selectively reduced in Parkinson's disease. The selective loss of lysosomal glucocerebrosidase was directly related to reduced lysosomal chaperone-mediated autophagy, increased α-synuclein and decreased ceramide. Glucocerebrosidase deficits in sporadic Parkinson's disease are related to the abnormal accumulation of α-synuclein and are associated with substantial alterations in lysosomal chaperone-mediated autophagy pathways and lipid metabolism. Our data suggest that the early selective Parkinson's disease changes are likely a result of the redistribution of cellular membrane proteins leading to a chronic reduction in lysosome function in brain regions vulnerable to Parkinson's disease pathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, loss‐of‐function mutations in GBA disrupt the autophagic flux and lead to the aggregation of SNCA/α‐synuclein (Murphy et al, 2014).”
From Autophagy in major human diseases (2021) · cites this paper as Murphy et al, 2014
Citations
Cites
1 retracted
Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., Hansen, L., Adame, A., Galasko, D., & Masliah, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009313 · Cited by 367
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
How to Interpret LC3 Immunoblotting
Mizushima, N., & Yoshimori, T. (2007) · Autophagy · doi:10.4161/auto.4600 · Cited by 2,669
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationImpaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Morris, J. C. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004870 · Cited by 1,641
Lysosomal membrane permeabilization in cell death
Boya, P., & Kroemer, G. (2008) · Oncogene · doi:10.1038/onc.2008.310 · Cited by 1,426
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Self-citation
Research works printed but not linked: 1
- Stone, 2000, Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease, Hum Mutat, 15, 181, 10.1002/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.0.CO;2-S · DOI · Paper page
Cited by
Items 201–300 of 475
Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid
Boman, A., Svensson, S., Boxer, A. L., Rojas, J. C., Seeley, W. W., Karydas, A., Miller, B. L., Kågedal, K., & Svenningsson, P. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-150759 · Cited by 39
“It has been previously described that levels of LAMP-2 are decreased early in the disease progression in the PD brain [10, 21].”
BackgroundGBA mutations in Parkinson disease: earlier death but similar neuropathological features
Adler, C. H., Beach, T. G., Shill, H. A., Caviness, J. N., Driver‐Dunckley, E. D., Sabbagh, M. N., Patel, A., Sue, L. I., Serrano, G. E., Jacobson, S. A., et al. (2017) · European Journal of Neurology · doi:10.1111/ene.13395 · Cited by 40
Kim, D., Hwang, H., Choi, S., Kwon, S. H., Lee, S.-H., Park, J. H., Kim, S., & Ko, H. S. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0538-9 · Cited by 36
“Consistent with previous findings, our observations confirm that decreased GBA1 enzyme activity due to GBA1 mutations or null leads to increased α-synuclein levels in other models [8, 10, 30] and PD postmortem brains [11, 31].”
BackgroundResultProtein Kinase C Isozymes and Autophagy during Neurodegenerative Disease Progression
Kaleli, H. N., Ozer, E., Kaya, V. O., & Kutlu, Ö. (2020) · Cells · doi:10.3390/cells9030553 · Cited by 37
Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection
Pirooznia, S. K., Rosenthal, L. S., Dawson, V. L., & Dawson, T. M. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000189 · Cited by 37
α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies
Bigi, A., Cascella, R., & Cecchi, C. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.371345 · Cited by 40
“Accordingly, reductions in LAMP2 and LAMP2A have been observed in the brain tissue of PD patients (Alvarez et al., 2010; Murphy et al., 2014).”
BackgroundA Cleaning Crew: The Pursuit of Autophagy in Parkinson’s Disease
Parekh, P., Sharma, N., Gadepalli, A., Shahane, A., Sharma, M., & Khairnar, A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00244 · Cited by 34
Kim, M. J., Jeong, H., & Krainc, D. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac047 · Cited by 36
Yang, J., Hertz, E., Zhang, X., Leinartaité, L., Lundius, E. G., Li, J., & Svenningsson, P. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.11.023 · Cited by 37
Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment
Schapira, A. H. V., Chiasserini, D., Beccari, T., & Parnetti, L. (2016) · Movement Disorders · doi:10.1002/mds.26616 · Cited by 38
“However, in agreement with Gegg and colleagues, there was no change in the level of GBA mRNA in the anterior cingulate cortex, nor an alteration of LIMP-2 levels.(32) Interestingly, an increased alphasynuclein level and decreased amount of ceramide were observed, thus supporting the possible role of GCase deficiency i…”
ResultSensory neuropathy and nociception in rodent models of Parkinson's disease
Valek, L., Auburger, G. W. J., & Tegeder, I. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.039396 · Cited by 37
“Indeed, a strong link has been established between PD and lysosomal storage disorders (Aflaki et al., 2017; MigdalskaRichards et al., 2017; Murphy et al., 2014; Rocha et al., 2015; Stojkovska et al., 2018; Zunke et al., 2018), some of which are characterized by serious pain (Godel et al., 2017;…”
BackgroundJin, J. W., Fan, X., del Cid‐Pellitero, E., Liu, X., Zhou, L., Dai, C., Gibbs, E., He, W., Li, H., Wu, X., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01746-6 · Cited by 42
Wakhloo, D., Mahajani, S. U., Oberhauser, J., & Madira, A. E. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.336138 · Cited by 42
“Other positive factors include diet (Murphy et al., 2014), neurotrophins (Bonafina et al., 2020), and sleep (Kumar et al., 2020).”
Riboldi, G. M., Vialle, R. A., Navarro, E., Udine, E., Lopes, K. D. P., Humphrey, J., Allan, A., Parks, M., Henderson, B., Astudillo, K., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00554-8 · Cited by 35
Congdon, E. E., Pan, R., Jiang, Y., Sandusky‐Beltran, L. A., Dodge, A., Lin, Y., Liu, M., Kuo, M., Kong, X., & Sigurdsson, E. M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104249 · Cited by 35
Oftedal, L., Maple‐Grødem, J., Dalen, I., Tysnes, O., Pedersen, K. F., Alves, G. W., & Lange, J. (2022) · Neurology · doi:10.1212/wnl.0000000000201418 · Cited by 38
“Previously published CSF amyloid β1-42 concentrations, 19 measured by ELISA (Innotest β -amyloid(1-42), Fujirebio,”
The Future of Research in Parkinson Disease
Jankovic, J. J., & Sherer, T. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1717 · Cited by 33
Role of GSK3β/α-synuclein axis in methamphetamine-induced neurotoxicity in PC12 cells
Li, L., Chen, S. X., Wang, Y., Yue, X., Xu, J., Xie, W., Qiu, P., Liu, C., Wang, A., & Wang, H. (2018) · Toxicology Research · doi:10.1039/c7tx00189d · Cited by 33
Lysosomal Storage Disorders Shed Light on Lysosomal Dysfunction in Parkinson’s Disease
Blumenreich, S., Barav, O. B., Jenkins, B., & Futerman, A. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144966 · Cited by 36
“Also, the selective reduction of LAMP2 and GCase in regions accumulating α-synuclein in the early stages of PD was observed, suggesting altered lysosomal function, including alterations in chaperone-mediated autophagy pathways [69].”
BackgroundBenz, J., Rufer, A. C., Huber, S., Ehler, A., Hug, M. N., Topp, A., Guba, W., Hofmann, E. C., Jagasia, R., & Sarmiento, R. M. R. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202013890 · Cited by 33
Padilla-Godínez, F. J., Ramos-Acevedo, R., Martínez-Becerril, H. A., Bernal-Conde, L. D., Garrido-Figueroa, J. F., Hiriart, M., Hernández-López, A., Argüero‐Sánchez, R., Callea, F., & Guerra‐Crespo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212467 · Cited by 34
“Over the years, it has been established that GCase activity and content decrease in SNpc and other brain regions in different studies of patients with sporadic PD [83,84].”
BackgroundResearch Priorities on the Role of α‐ Synuclein in Parkinson's Disease Pathogenesis
Burré, J., Edwards, R. H., Halliday, G. M., Lang, A. E., Lashuel, H. A., Melki, R., Murayama, S., Outeiro, T. F., Papa, S. M., Stefanis, L., et al. (2024) · Movement Disorders · doi:10.1002/mds.29897 · Cited by 36
Self-citationLeukocyte glucocerebrosidase and β-hexosaminidase activity in sporadic and genetic Parkinson disease
Kim, H., Jeon, B., Song, J., Lee, W., Park, H.-Y., & Shin, C. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.12.002 · Cited by 33
Autophagy and lysosomal pathways in nervous system disorders
Bingol, B. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.04.009 · Cited by 35
Brekk, O. R., Moskites, A., Isacson, O., & Hallett, P. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-33474-z · Cited by 34
Viel, C., Clarke, J. L., Kayatekin, C., Richards, A. M., Chiang, M. S. R., Park, H. J., Wang, B., Shihabuddin, L. S., & Sardi, S. P. (2021) · Scientific Reports · doi:10.1038/s41598-021-00404-5 · Cited by 33
Lang, M., Pramstaller, P. P., & Pichler, I. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00555-7 · Cited by 40
Genetic Movement Disorders in Patients of Jewish Ancestry
Inzelberg, R., Hassin‐Baer, S., & Jankovic, J. J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1364 · Cited by 31
Autophagy dysfunction in peripheral blood mononuclear cells of Parkinson’s disease patients
Papagiannakis, N., Xilouri, M., Koros, C., Simitsi, A., Stamelou, M., Maniati, M., & Stefanis, L. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.04.003 · Cited by 33
Hughes, L. P., Pereira, M., Hammond, D. A., Kwok, J. B., Halliday, G. M., Lewis, S. J. G., & Dzamko, N. L. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202508 · Cited by 30
“Sanger sequencing of GBA1 was performed using long-range PCR, as we have published before [6, 15].”
MethodSelf-citationMingione, A., Pivari, F., Plotegher, N., Dei, M., Zulueta, A., Bocci, T., Trinchera, M., Albi, E., Maglione, V., Caretti, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126469 · Cited by 32
“Sphingomyelins and ceramides are increased in postmortem PD brains compared to those of healthy subjects [8,38,43], and it is notable that there is a marked increase in the transcription of the enzymes responsible for de novo sphingolipid synthesis [38].”
BackgroundSharma, S., & Priya, S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2340-9 · Cited by 34
Glucocerebrosidase as a therapeutic target for Parkinson’s disease
Chen, Y., Sam, R., Sharma, P., Chen, L., Do, J., & Sidransky, E. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1733970 · Cited by 32
Self-citationAlbanese, F., Mercatelli, D., Finetti, L., Lamonaca, G., Pizzi, S., Shimshek, D. R., Bernacchia, G., & Morari, M. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105487 · Cited by 30
Plasma sphingolipid abnormalities in neurodegenerative diseases
Oizumi, H., Sugimura, Y., Totsune, T., Kawasaki, I., Ohshiro, S., Baba, T., Kimpara, T., Sakuma, H., Hasegawa, T., Kawahata, K., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279315 · Cited by 36
“In the pathological brain tissue of IPD patients without GBA1 mutations, GCase activity was also reported to be decreased [61].”
BackgroundTransmembrane Protein 175, a Lysosomal Ion Channel Related to Parkinson’s Disease
Tang, T., Jian, B., & Liu, Z. (2023) · Biomolecules · doi:10.3390/biom13050802 · Cited by 33
Parrella, E., Bellucci, A., Porrini, V., Benarese, M., Lanzillotta, A., Faustini, G., Longhena, F., Abate, G., Uberti, D. L., & Pizzi, M. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0154-z · Cited by 38
Isacson, O., Brekk, O. R., & Hallett, P. J. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01053 · Cited by 32
Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial
Silveira, C. R. A., Coleman, K. K. L., Borron, K., Tirona, R. G., Rupar, C. A., Zou, G., Hegele, R. A., Wellington, C. L., Stukas, S. K., Finger, E. C., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.1687 · Cited by 41
New Directions in Gaucher Disease
Horowitz, M., Elstein, D., Zimran, A., & Göker-Alpan, Ö. (2016) · Human Mutation · doi:10.1002/humu.23056 · Cited by 36
“…GCase in the ER of dopaminergic cells (and potentially in other as yet unknown cells) leads to ER stress, and as a consequent (possibly) to α-synuclein accumulation and cell death, thereby inducing development of PD [Boyd and Valenzano, 2014; Murphy et al., 2014; Murphy and Halliday, 2014].”
BackgroundConvergent pathways in Parkinson’s disease
Cherubini, M., & Wade‐Martins, R. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2700-2 · Cited by 31
“reduced without GBA mutations and is associated with lysosomal dysfunction and accumulation of αSyn (Murphy et al. 2014).”
BackgroundFeng, S., Rcheulishvili, N., Jiang, X., Zhu, P., Pan, X., Wei, M., Wang, P. G., Ji, Y., & Papukashvili, D. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.87741 · Cited by 33
“Remarkably, patients with PD without GBA1 mutations also have lowered levels of GCase (98).”
BackgroundWilliams, D., Glasstetter, L. M., Jong, T. T., Chen, T., Kapoor, A., Zhu, S., Zhu, Y., Calvo, R., Gehrlein, A., Wong, K., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2406009121 · Cited by 34
“Yet, interventions targeting GCase - WT could have considerable impact for the broader PD population, as it has been reported that, even in idiopathic PD, GCase levels tend to be low, reflecting an inverse relationship between GCase and α-synuclein (82).”
Self-citationFu, Y., Zhang, J., Qin, R., Ren, Y., Zhou, T., Han, B., & Liu, B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100053 · Cited by 35
Ramezani, M., Wilkes, M. M., Das, T., Holowka, D., Eliezer, D., & Baird, B. A. (2019) · npj Parkinson s Disease · doi:10.1038/s41531-019-0084-6 · Cited by 30
“terminal truncation (1-102)) created using site-directed mutagenesis (Agilent QuikChange) were confirmed by Sanger sequencing.”
BackgroundMethodLee, H., & Koh, J. (2020) · Glia · doi:10.1002/glia.23952 · Cited by 31
“…demonstrated to cause lysosomal dysfunction, notably including the dissipation of the luminal acidity required for optimal functioning of lysosomal enzymes (Coffey, Beckel, Laties, & Mitchell, 2014; Dehay et al., 2013; Mazzulli et al., 2011; Murphy et al., 2014; Nixon, 2013; Varga et al., 2015).”
BackgroundWallings, R. L., Hughes, L. P., Staley, H. A., Simon, Z. D., McFarland, N. R., Alcalay, R. N., Garrido, A., Martí, M. J., Sarró, E. T., Dzamko, N. L., et al. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.892899 · Cited by 25
“It has previously been demonstrated that GCase activity is reduced in pathologically affected brain tissue (Murphy et al., 2014) and monocytes (Atashrazm et al.”
BackgroundFactors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid
Persichetti, E., Chiasserini, D., Parnetti, L., Eusebi, P., Paciotti, S., Carlo, C. D., Codini, M., Tambasco, N., Rossi, A., El‐Agnaf, O. M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101453 · Cited by 29
“Alterations in lysosomal chaperonemediated autophagy have been demonstrated to cause the reduction of b-glucocerebrosidase protein levels and activity in the brain of early stage PD patients, especially in brain regions showing increased a-synuclein levels (14).”
BackgroundRole of endolysosomes and inter-organellar signaling in brain disease
Afghah, Z., Chen, X., & Geiger, J. D. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104670 · Cited by 29
In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons
Fouka, M., Mavroeidi, P., Tsaka, G., & Xilouri, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.559791 · Cited by 29
“…accumulation and GCase protein levels and activity where reduced GCase activity coincides with increased levels of α-synuclein (Mazzulli et al., 2011; Osellame et al., 2013; Sardi et al., 2013; Murphy et al., 2014; Du et al., 2015; Liu et al., 2015; Rocha et al., 2015; Chen M.et al., 2016).”
BackgroundWhat have we learned from genome-wide association studies (GWAS) in Parkinson's disease?
Fernández‐Santiago, R., & Sharma, M. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101648 · Cited by 28
“Subsequent GWAS with larger sample sizes confirmed these loci and suggested population-specific effects (IPDGC and WTCCC2, 2011; Nalls et al., 2014, 2019; Chang et al., 2017).”
BackgroundMethodResultInfluentialGaucher-Associated Parkinsonism
Li, Y., Li, P., Liang, H., Zhao, Z., Hashimoto, M., & Wei, J. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0176-8 · Cited by 26
“GCase deficits in sporadic Parkinson’s disease are related to the abnormal accumulation of a-syn (Murphy et al. 2014).”
BackgroundAnalysis of age-related changes in psychosine metabolism in the human brain
Marshall, M. S., Jakubauskas, B., Bogue, W., Stoskute, M., Hauck, Z., Rue, E. A., Nichols, M., DiAntonio, L. L., van Breemen, R. B., Kordower, J. H., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193438 · Cited by 27
Chen, M., Yang, W., Li, X., Li, X., Wang, P., Yue, F., Yang, H., Chan, P., & Yu, S. (2015) · Oncotarget · doi:10.18632/oncotarget.6445 · Cited by 34
“In the brains of patients with PD, there is a reduction in GCase activity and ceramide levels [38].”
BackgroundCSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB
Lerche, S., Sjödin, S., Brinkmalm, A., Blennow, K., Wurster, I., Röeben, B., Zimmermann, M., Hauser, A., Liepelt‐Scarfone, I., Waniek, K., et al. (2021) · Movement Disorders · doi:10.1002/mds.28704 · Cited by 25
Westbroek, W., Nguyen, M. H., Siebert, M., Lindstrom, T., Burnett, R. A., Aflaki, E., Jung, O., Tamargo, R. J., Rodriguez‐Gil, J. L., Acosta, W. L., et al. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.024588 · Cited by 29
“Furthermore, GCase enzyme activity and protein expression levels are reduced in select brain regions of individuals with PD without GBA1 mutations (Murphy et al., 2014; Gegg et al., 2012).”
Self-citationThomas, R., Moloney, E. B., Macbain, Z. K., Hallett, P. J., & Isacson, O. (2021) · Molecular Brain · doi:10.1186/s13041-020-00712-3 · Cited by 30
Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease
Matrone, C., Dzamko, N. L., Madsen, P., Nyegaard, M., Pohlmann, R., Søndergaard, R. V., Lassen, L. B., Andresen, T. L., Halliday, G. M., Jensen, P. H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160501 · Cited by 24
Self-citationAbe, T., & Kuwahara, T. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.681369 · Cited by 28
“The association between reduced GCase and increased α-synuclein is further implicated in human PD postmortem brains (157).”
BackgroundAbbott, S. K., Jenner, A. M., Spiro, A. S., Batterham, M. J., Halliday, G. M., & Garner, B. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-140479 · Cited by 30
“Since we have recently documented that neuronal loss does not occur in these early Braak stage cases [51], the alterations in fatty acid composition we have detected are not likely to be related to neuronal loss per se.”
Self-citationFarotti, L., Paciotti, S., Tasegian, A., Eusebi, P., & Parnetti, L. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1341312 · Cited by 26
“GCase-positive LBs were described in brains from PD GBA1 mutation carriers [82,83].”
BackgroundHahnefeld, L., Vogel, A., Gurke, R., Geißlinger, G., Schäfer, M. K. E., & Tegeder, I. (2022) · Biomedicines · doi:10.3390/biomedicines10040914 · Cited by 26
Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels
Vruchte, D. T., Sturchio, A., Priestman, D. A., Tsitsi, P., Hertz, E., Andréasson, M., Markaki, I., Wallom, K., Platt, F. M., & Svenningsson, P. (2022) · Movement Disorders · doi:10.1002/mds.29163 · Cited by 23
Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?
Roberts, B., Theunissen, F., Mastaglia, F. L., Akkari, P. A., & Flynn, L. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169364 · Cited by 25
Aneuploidy in Lewy body diseases
Yang, Y., Shepherd, C. E., & Halliday, G. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.016 · Cited by 24
“in the anterior cingulate cortex microscopically, consistent with evidence using other methods (Murphy et al., 2014), although there was an increase in the numbers of large-sized and all nuclei in this region.”
Self-citationLysosomal enzyme activities as possible CSF biomarkers of synucleinopathies
Paciotti, S., Gatticchi, L., Beccari, T., & Parnetti, L. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.03.1627 · Cited by 26
The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease
Burbulla, L. F., & Krainc, D. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104545 · Cited by 23
Prodromal sensory neuropathy in Pink1 −/− SNCA A53T double mutant Parkinson mice
Valek, L., Tran, B., Wilken‐Schmitz, A., Trautmann, S., Heidler, J., Schmid, T., Brüne, B., Thomas, D., Deller, T., Geißlinger, G., et al. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12734 · Cited by 24
Altered expression of glycobiology-related genes in Parkinson’s disease brain
Schneider, J. S., & Singh, G. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1078854 · Cited by 27
Yu, M., Ye, H., De-Paula, R. B., Mangleburg, C. G., Wu, T., Lee, T. V., Li, Y., Duong, D. M., Phillips, B., Cruchaga, C., et al. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010760 · Cited by 25
GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies
Johnson, P. H., Weinreb, N. J., Cloyd, J. C., Tuite, P., & Kartha, R. V. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.10.006 · Cited by 23
“In the absence of a GBA1 mutation, iPD patients appear to have lower GCase activity compared to controls [69, 70].”
BackgroundSiemeling, O., Slingerland, S., van der Zee, S., & van Laar, T. (2024) · BMC Neurology · doi:10.1186/s12883-024-03629-9 · Cited by 24
“…baseline and 60 weeks, and include safety/tolerability of ambroxol, change in GCase activity in monocytes, striatal F-DOPA uptake as measured by [18]F-DOPA PET scans of the brain, resting state fMRI, related to structural MRI and diffusion tensor imaging (DTI) tractography, quality of life…”
MethodLi, X., Yang, W., Li, X., Li, X., Li, W., Song, Q., Sun, L., Lin, F., Chen, Z., Wang, C., et al. (2020) · Parkinson s Disease · doi:10.1155/2020/8740419 · Cited by 25
“For example, the levels of the total, oligomeric, and phosphorylated α-syn were shown to be elevated in the RBCs of PD patients [16, 18], and these forms of α-syn were reported to be also increased in the brain of PD patients [20, 28, 29].”
BackgroundGenetic testing in dementia‐A medical genetics perspective
Huq, A. J., Sexton, A., Lacaze, P. A., Masters, C. L., Storey, E., Velakoulis, D., James, P. A., & Winship, I. (2021) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5535 · Cited by 24
“Gaucher disease, a lysosomal storage disorder when biallelic mutations are found, acts as a risk factor for PD with dementia.(107,108) In particular, two variants in GBA c.”
BackgroundClinical Sphingolipids Pathway in Parkinson’s Disease: From GCase to Integrated-Biomarker Discovery
Esfandiary, A., Finkelstein, D. I., Voelcker, N. H., & Rudd, D. A. (2022) · Cells · doi:10.3390/cells11081353 · Cited by 23
“In these independently conducted studies on the SN tissues of PD-GBA wild type cases, the GCase enzyme catalytic activity is reduced as well as its mRNA and protein levels [35,36,72].”
BackgroundRefining the clinical diagnosis of Parkinson's disease
Mulroy, E., Erro, R., Bhatia, K. P., & Hallett, M. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106041 · Cited by 28
Manecka, D.-L., Vanderperre, B., Fon, E. A., & Durcan, T. M. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00311 · Cited by 21
Research Advances in Chaperone-Mediated Autophagy (CMA) and CMA-Based Protein Degraders
Pan, Z., Huang, X., Liu, M., Jiang, X. L., & He, G. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02681 · Cited by 23
L‐DOPA regulates α‐synuclein accumulation in experimental parkinsonism
Deffains, M., Canron, M., Teil, M., Li, Q., Dehay, B., Bézard, E., & Fernagut, P. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12678 · Cited by 22
Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways
Vieira, S. R. L., & Schapira, A. H. V. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.08.230 · Cited by 19
Impact of endolysosomal dysfunction upon exosomes in neurodegenerative diseases
Izco, M., Carlos, E., & Alvarez‐Erviti, L. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105651 · Cited by 19
“Interestingly, a decrease in GBA activity has been found in sporadic PD patients without mutations (Gegg et al., 2012; Murphy et al., 2014; Rocha et al., 2015).”
BackgroundLysosomal Enzyme Glucocerebrosidase Protects against Aβ1-42 Oligomer-Induced Neurotoxicity
Choi, S., Kim, D., Kam, T., Yun, S., Kim, S., Park, H., Hwang, H., Pletniková, O., Troncoso, J. C., Dawson, V. L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143854 · Cited by 22
Tripathi, M. K., Rajput, C., Mishra, S., Rasheed, M. S. U., & Singh, M. P. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9917-z · Cited by 21
Lipids as Trans-Acting Effectors for α-Synuclein in the Pathogenesis of Parkinson’s Disease
Ikenaka, K., Suzuki, M., Mochizuki, H., & Nagai, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00693 · Cited by 24
“Furthermore, a decrease in GCase activity in the brains of sporadic PD/DLB patients was reported to be associated with an increase in the amounts of insoluble αSyn (Murphy et al., 2014).”
BackgroundWang, P., Li, X., Li, X., Yang, W., & Yu, S. (2016) · Parkinson s Disease · doi:10.1155/2016/7596482 · Cited by 23
Lipid excess affects chaperone-mediated autophagy in hypothalamus
Portovedo, M., Reginato, A., Miyamoto, J. É., Simino, L. A. D. P., Hakim, M. P., Campaña, M. B., Leal, R. F., Ignácio-Souza, L. M., Torsoni, M. A., Magnan, C., et al. (2020) · Biochimie · doi:10.1016/j.biochi.2020.06.008 · Cited by 20
Shamir, D. B., Deng, Y., Wu, Q., Modak, S., Congdon, E. E., & Sigurdsson, E. M. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.602292 · Cited by 19
Lunghi, G., Carsana, E. V., Loberto, N., Cioccarelli, L., Prioni, S., Mauri, L., Bassi, R., Duga, S., Straniero, L., Asselta, R., et al. (2022) · Cells · doi:10.3390/cells11152343 · Cited by 21
“Interestingly, the accumulation of alpha-synuclein within lysosomes has been associated with a chronic reduction in lysosomal function [10,11].”
BackgroundCrosstalk between sphingolipids and vitamin D3: potential role in the nervous system
Garcia‐Gil, M., Pierucci, F., Vestri, A., & Meacci, E. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13726 · Cited by 19
“…areas 46, 10,20 patients, B – ↑ PPAP2B, ↑ SPL, ↓acid CDase, ↑CERS1,2, ↓CERS6 Katsel et al., 2007 PD Anterior cingulate cortex, patients B – ↓total Cer, ↓SM, ↑CERS1 expression Abbott et al., 2014 Anterior cingulate cortex, patients B ↑ autophagy ↑α-synuclein ↓glucosylCDase, ↓Cer, Murphy…”
BackgroundPuska, G., Lutz, M. I., Molnár, K., Regelsberger, G., Ricken, G., Pirker, W., László, L., & Kovács, G. G. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.02.019 · Cited by 20
When lipid homeostasis runs havoc: Lipotoxicity links lysosomal dysfunction to autophagy
Tegeder, I., & Kögel, D. (2020) · Matrix Biology · doi:10.1016/j.matbio.2020.11.005 · Cited by 22
Shi, C., Zheng, Z., Wang, Q., Wang, C., Zhang, D., Zhang, M., Chan, P., & Wang, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155758 · Cited by 19
Wang, L., Liu, L., Han, C., Jiang, H., Ma, K., Guo, S., Xia, Y. F., Wan, F. J., Huang, J., Xiong, N., et al. (2023) · Brain Sciences · doi:10.3390/brainsci13040670 · Cited by 22
“For example, it has been found that Beclin-1 expression levels increased significantly in the substantia nigra [52], but decreased in the anterior cingulate cortex of PD patients [53].”
BackgroundJensen, N. M., Fu, Y., Betzer, C., Li, H., Elfarrash, S., Shaib, A., Krah, D., Vitic, Z., Reimer, L., Gram, H., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00841-9 · Cited by 27
“As we have shown previously the anterior cingulate cortex (ACC) has staged α -synuclein changes in PD with increased levels but limited LBs at stageIV progressing tosigni fi cantLBsby stageVI 67 , werequested formalin-fi xedparaf fi n-embedded(FFPE)tissuesectionsfromtheACCforthisstudy.”
Self-citationLRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome
Maloney, M. T., Wang, X., Ghosh, R., Andrews, S. V., Maciuca, R. D., Masoud, S. T., Agam, M. R., Caprioli, R. M., Astarita, G., Bondar, V. V., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00880-7 · Cited by 21
“Variants in GBA1 are observed in approximately 10% of PD patients, and increasing data, including that reported in the present work, suggest that GCase activity is impaired in PD patients beyond those that carry deleterious GBA1 variants [8, 89–92].”
Baden, P., Yu, C., & Deleidi, M. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.01.023 · Cited by 17
Carandina, A., Lazzeri, G., Rodrigues, G. D., Franco, G., Monfrini, E., Arienti, F., Frattini, E., Trezzi, I., Soares, P. P. D. S., Bellocchi, C., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.842498 · Cited by 22
Beger, A. W., Dudzik, B., Woltjer, R. L., & Wood, P. L. (2022) · Metabolites · doi:10.3390/metabo12020187 · Cited by 22
“This disrupted homeostasis has been linked to a-synuclein aggregation [55,56].”
BackgroundThe synaptic lipidome in health and disease
Vallés, A. S., & Barrantes, F. J. (2022) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2022.184033 · Cited by 17
Pathological Pathways and Alpha-Synuclein in Parkinson's Disease: A View from the Periphery
Basellini, M. J., Kothuis, J. M., Comincini, A., Pezzoli, G., Cappelletti, G., & Mazzetti, S. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2802033 · Cited by 21
“This mutation is causative for Gaucher disease, a lysosomal storage disorder [141], and a decreased enzyme activity has been reported in PD patients with or without GBA1 mutations [142].”
Background
Metadata
- Authors
- Murphy, K. E., Gysbers, A. M., Abbott, S. K., Tayebi, N., Kim, W. S., Sidransky, E., Cooper, A., Garner, B., & Halliday, G. M.
- Affiliations
- UNSW Sydney (AU)
- Neuroscience Research Australia (AU)
- University of Wollongong (AU)
- National Institutes of Health (US)
- Garvan Institute of Medical Research (AU)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-28
- Volume
- 137
- Issue
- 3
- Pages
- 834-848
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC3927701
- OpenAlex
- W2144140825
- Cited by
- 475
- References
- 85
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 37 · 2023: 31 · 2022: 39 · 2021: 52 · 2020: 54 · 2019: 49 · 2018: 30 · 2017: 34 · 2016: 42 · 2015: 42 · 2014: 15
- FWCI
- 29.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Figshare (submittedVersion, cc-by)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (R24AA012725, R28AA012725)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, alpha-synuclein, GBA1, sporadic Parkinson's disease, lysosomal dysfunction, chaperone-mediated autophagy, ceramide, sphingolipids, early-stage Parkinson's disease, brain regions, inclusion formation
- MeSH terms
- Aged, Aged, 80 and over, Autophagy, Brain, Female, Glucosylceramidase, Humans, Lysosomes, Male, Mutation, Parkinson Disease, Cohort Studies, Up-Regulation, Case-Control Studies, Molecular Chaperones, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.